<DOC>
	<DOCNO>NCT01657929</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability , immunogenicity healthy adult subject investigational vaccine develop prevention pandemic influenza . The vaccine , identify H5-VLP + GLA-AF , consist recombinant influenza virus H5 protein ( hemagglutinin A/Indonesia/5/2005 ) produce plant-based expression system assemble virus-like particle together adjuvant GLA-AF .</brief_summary>
	<brief_title>H5-VLP + GLA-AF Vaccine Trial Healthy Adult Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Influenza Birds</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<criteria>Males females 18 49 year age . Must good general health confirm medical history physical exam , vital sign , screen laboratory conduct 30 day prior study injection administration . Female subject childbearing potential , regardless birth control history , must negative serum pregnancy test screening , negative urine pregnancy test day study injection , must breastfeed lactating , require consistently use one follow method contraception first three month study : hormonal ( e.g . oral , transdermal , intravaginal , implant , injection ) ; double barrier ( i.e. , condom , diaphragm spermicide ) ; intrauterine device ( IUD ) system ( IUS ) ; vasectomize partner ( 6 month minimum ) ; abstinence ( confirmed investigator ) ; bilateral tubal ligation ( conception postprocedure ) . These precaution necessary due unknown effect H5VLP + GLA AF H5VLP alone might fetus newborn infant . The subject must plan become pregnant first three month study period . Females postmenopausal ( spot ) least one ( 1 ) year require pregnancy test . The follow screening laboratory blood test must value within normal range ( provided clinical site ) clinically significant determine Principal Investigator ( designate subinvestigator ) Medical Monitor ( test result must within 30 day prior first study injection ) : sodium , potassium , BUN , ALT , AST , total bilirubin , alkaline phosphatase , creatinine , fast glucose , fast lipid panel , total WBC count , hemoglobin , platelet count . The following serology test must negative : HIV 1/2 antibody , hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) antibody . Negative urine test recreational drug alcohol per Clinical Research Unit standard . Urinalysis clinically significant determine study clinician . In opinion Investigator , must show comprehension study requirement , competence willingness provide write , informed consent participation reading inform consent form . The subject must adequate opportunity discus study Investigator qualify designee . Must capable completing study memory aid English . Must able willing attend evaluation visit , reachable telephone consistent basis study site personnel , permanent address . Previous exposure H5N1 vaccine experimental product contain GLAAF . History allergy constituent H5VLP ( H5N1 ) + Alhydrogel ( aluminum hydroxide ) vaccine . Participation another experimental protocol receipt investigational nonregistered product within past 3 month plan use study period . Subjects may participate drug study participate study . Treatment immunosuppressive drug ( e.g. , oral injected steroid , prednisone ; high dose inhaled steroid ) cytotoxic therapy ( e.g. , chemotherapy drug radiation ) within past 6 month . Received blood transfusion immunoglobulin within past 3 month . Donated blood product ( platelet , whole blood , plasma , etc . ) within past 1 month . Poor venous access . Administration vaccine ( include influenza vaccine ) within 30 day period prior study enrollment , plan administration vaccine within period first study injection blood sample Day 42 within 30 day prior blood sample Day 189 . Immunization emergency basis tetanus diphtheria toxoid adsorb adult use ( Td ) allow provide vaccine administer within two week prior study injection administration . Receipt emergency immunization ( e.g . rabies ) result casebycase review continue participation . History autoimmune disease cause immunosuppressive state . Any confirm suspected immunosuppressive condition immunodeficiency include history human immunodeficiency virus ( HIV ) infection presence lymphoproliferative disease . History evidence acute chronic illness ( include cardiovascular , pulmonary , neurological , hepatic , rheumatic , hematological , metabolic , renal disorder , control hypertension ) , use medication , opinion Principal Investigator ( designate subinvestigator ) , may interfere evaluation safety immunogenicity vaccine . Cancer treatment cancer within 3 year study injection administration . Persons history cancer diseasefree without treatment 3 year eligible . Persons treat uncomplicated basal cell carcinoma skin eligible . Presence significant acute chronic , uncontrolled medical neuropsychiatric illness . `` Uncontrolled '' define : Requiring new medical surgical treatment within one month prior study vaccine administration Requiring change medication dosage one month prior test article administration due uncontrolled symptom drug toxicity ( elective dosage adjustment stable subject acceptable ) , Hospitalization event fulfil definition serious adverse event within one month prior test article administration Rash , tattoos dermatological condition could adversely affect vaccine injection site interfere evaluation . BMI &lt; 18 &gt; 30 kg/m2 . Hypertension ( systolic ≥150 mmHg diastolic ≥90 mmHg ) . Resting pulse rate &lt; 40 bpm &gt; 100 bpm . Any medical neuropsychiatric condition , Investigator 's opinion , would render subject incompetent provide inform consent unable provide valid safety observation report . Known suspected alcohol drug abuse within past 6 month . Chronic smoker ( &gt; 20 pack year ) . History allergy tobacco egg . Subjects history previous anaphylaxis severe allergic reaction vaccine , unknown allergen . Subjects unlikely cooperate requirement study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Avian</keyword>
	<keyword>H5N1</keyword>
	<keyword>H5-VLP</keyword>
	<keyword>GLA</keyword>
	<keyword>GLA-AF</keyword>
</DOC>